Overview

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.

Phase:

Phase 1

Details

Lead Sponsor:

Allergan

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions
Timolol